We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+4.4%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.06B
AUM Growth
+$28.4M
Cap. Flow
-$1.31B
Cap. Flow %
-42.81%
Top 10 Hldgs %
37.02%
Holding
95
New
15
Increased
19
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$50.1M
2
BSX icon
Boston Scientific
BSX
+$37.5M
3
VRDN icon
Viridian Therapeutics
VRDN
+$30.9M
4
MRVI icon
Maravai LifeSciences
MRVI
+$24.4M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$21.7M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$90.4M
2
GKOS icon
Glaukos
GKOS
+$43.8M
3
AMGN icon
Amgen
AMGN
+$39M
4
ISRG icon
Intuitive Surgical
ISRG
+$30M
5
BLU
BELLUS Health Inc.
BLU
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 54.2%
2 Miscellaneous 45.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$15.7B
$88M 2.88%
933,362
+166,562
+22% +$16.3M
PCVX icon
2
Vaxcyte
PCVX
$8.9B
$86M 2.81%
1,722,353
+402,375
+30% +$19.1M
ALGN icon
3
Align Technology
ALGN
$11.2B
$79.2M 2.59%
224,030
+16,900
+8% +$5.38M
GKOS icon
4
Glaukos
GKOS
$10.6B
$74.4M 2.43%
1,044,392
-762,259
-42% -$43.8M
XENE icon
5
Xenon Pharmaceuticals
XENE
$5.81B
$70.4M 2.3%
1,828,353
-308,757
-14% -$12.3M
NTRA icon
6
Natera
NTRA
$47B
$56.1M 1.83%
1,152,851
+170,610
+17% +$8.7M
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$51.3M 1.68%
3,646,419
+405,068
+12% +$5.8M
IRTC icon
8
iRhythm Holdings
IRTC
$3.96B
$49.9M 1.63%
478,557
+24,388
+5% +$2.93M
DICE
9
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$47.8M 1.56%
1,029,901
+45,101
+5% +$1.56M
KROS icon
10
Keros Therapeutics
KROS
$219M
$46M 1.5%
+1,143,865
New +$50.1M
NVRO
11
DELISTED
NEVRO CORP.
NVRO
$45.2M 1.48%
1,776,368
+143,453
+9% +$4.14M
ISRG icon
12
Intuitive Surgical
ISRG
$132B
$42.3M 1.38%
123,820
-99,300
-45% -$30M
MRUS
13
DELISTED
Merus
MRUS
$40.6M 1.33%
1,543,162
+70,078
+5% +$1.53M
DAWN
14
DELISTED
Day One Biopharmaceuticals
DAWN
$40.1M 1.31%
3,361,813
+201,918
+6% +$2.64M
BSX icon
15
Boston Scientific
BSX
$67.9B
$38.8M 1.27%
+717,050
New +$37.5M
LEGN icon
16
Legend Biotech
LEGN
$3.87B
$38.4M 1.25%
556,301
-45,500
-8% -$2.97M
FNA
17
DELISTED
Paragon 28, Inc.
FNA
$37.9M 1.24%
2,136,122
+1,037,400
+94% +$18.6M
BIIB icon
18
Biogen
BIIB
$32.3B
$34.7M 1.14%
121,942
-98,800
-45% -$29.4M
KIDS icon
19
OrthoPediatrics
KIDS
$617M
$33.4M 1.09%
761,208
-237,663
-24% -$11M
OM icon
20
Outset Medical
OM
$74.1M
$31.9M 1.04%
97,358
-19,599
-17% -$5.98M
ACRS icon
21
Aclaris Therapeutics
ACRS
$885M
$30.1M 0.98%
2,901,194
-367,900
-11% -$3.33M
AXNX
22
DELISTED
Axonics, Inc. Common Stock
AXNX
$29M 0.95%
573,791
+407,087
+244% +$21.7M
VRDN icon
23
Viridian Therapeutics
VRDN
$2.61B
$28.7M 0.94%
+1,206,300
New +$30.9M
KRYS icon
24
Krystal Biotech
KRYS
$10.4B
$28.3M 0.93%
241,399
-106,637
-31% -$10.9M
IMCR icon
25
Immunocore
IMCR
$1.89B
$28.1M 0.92%
468,027
+41,917
+10% +$2.39M
1
2 3

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q2 2023 Portfolio in Review

As of Q2 2023, Braidwell held 95 positions worth $3.06B, up 0.94% from $3.03B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Braidwell withdrew a net $1.31B in Q2 2023, closing 14 positions and reducing 16 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $90.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 54% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in Keros Therapeutics worth $46M.

  • Braidwell's largest Q2 2023 buy was Keros Therapeutics: 1,143,865 shares worth $46M.
  • Braidwell added most to Axonics, Inc. Common Stock in Q2 2023, an estimated $21.7M increase.
  • Braidwell's biggest Q2 2023 reduction was Glaukos, cutting an estimated $43.8M.
  • Braidwell fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $90.4M.
  • Braidwell's ten largest holdings make up 37% of its $3.06B portfolio in Q2 2023.
  • Braidwell opened 15 new positions and closed 14 in Q2 2023.
  • Braidwell's portfolio value rose 0.94% quarter-over-quarter to $3.06B.

Based on Braidwell's 13F filing for Q2 2023, filed 14 Aug 2023.